Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Novo Nordisk (CSE: NOVOb, NYSE: NVO) raised its full-year 2025 guidance after stronger-than-expected demand for its blockbuster weight-loss drugs helped improve its earnings outlook. The Danish pharmaceutical company now expects annual sales and operating profit to decline by no more than 6% at constant exchange rates, an improvement from its previous forecast of a 4% to 12% decline.
Despite the upgraded outlook, Novo Nordisk shares fell sharply as investors reacted to weaker-than-expected sales of the new oral version of Wegovy and disappointing clinical trial results for its experimental obesity treatment, CagriSema. U.S.-listed shares dropped about 6% on Tuesday, while Copenhagen-listed stock declined more than 4% in early Wednesday trading.
During the second quarter, oral Wegovy generated sales of 3.2 billion Danish kroner (around $500 million), slightly below analysts’ expectations of 3.3 billion kroner. Meanwhile, the injectable version of Wegovy remained the company’s top performer, delivering 19.48 billion kroner in quarterly revenue.
Investor sentiment was also pressured by new trial data showing CagriSema lagged Eli Lilly’s tirzepatide in blood sugar control among patients with Type 2 diabetes. While CagriSema met the primary goal of demonstrating noninferior weight loss, with patients losing an average of 15.2% of body weight compared with 15.8% for tirzepatide, it failed to match its rival in reducing HbA1c levels. CagriSema lowered HbA1c by 1.9%, versus 2.2% achieved by tirzepatide.
Market analysts noted the results were weaker than expected, particularly because Novo Nordisk had aimed to demonstrate noninferiority across both primary endpoints. The outcome strengthens Eli Lilly’s competitive position in the rapidly expanding obesity and diabetes treatment market.
Novo Nordisk reported second-quarter adjusted sales of 78.49 billion Danish kroner, up 7% from a year earlier. Adjusted operating profit, a key metric for investors, increased 11% to 33.39 billion kroner, while net profit declined 21% to 20.99 billion kroner.
Although demand for Wegovy continues to support Novo Nordisk’s business, investors remain focused on pipeline performance and intensifying competition in the global weight-loss drug market.
